BiotechTube
Fesarius Therapeutics

Fesarius Therapeutics

Cambridge, United States· Est.
fesariustherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.0M

Overview

Fesarius Therapeutics is an early-stage biotech developing a first-of-its-kind hydrogel dermal regeneration template (hDRT) called DermiSphere™. The technology, based on a dual-density collagen hydrogel architecture, is designed to accelerate and improve the healing of severe wounds by promoting rapid cellular invasion and vascularization. Currently in the pre-clinical stage, the company is positioning its product as a significant innovation in a wound care market that has seen limited advancement. Fesarius operates as a private, pre-revenue company seeking to address a substantial unmet need in reconstructive surgery and chronic wound management.

Wound HealingDermal RegenerationReconstructive Surgery

Technology Platform

Proprietary dual-density collagen hydrogel platform for dermal regeneration. It combines a less-dense hydrogel with denser collagen microspheres to create a differential degradation scaffold that promotes rapid cellular invasion, vascularization, and stable neodermis formation.

Funding History

10
Total raised:$5.0M
Grant$349K
Grant$397K
Grant$954K
Grant$50K

Opportunities

The company targets a large and growing advanced wound care market with a first-of-its-kind hydrogel dermal regeneration template.
If clinical data validate its pre-clinical advantages—such as faster integration and vascularization—it could capture significant share in surgical and burn wound management.
The platform technology also holds potential for future expansion into other tissue engineering applications.

Risk Factors

The major risk is the failure of pre-clinical results to translate into human safety and efficacy.
As a pre-revenue private company, it is also highly dependent on securing additional funding to advance into costly clinical trials.
It must also navigate a complex regulatory pathway and ultimately compete with established products in a competitive market.

Competitive Landscape

Fesarius competes in the dermal substitute and advanced wound care market against established products like Integra's Dermal Regeneration Template, Smith & Nephew's skin substitutes, and other collagen-based matrices. It aims to differentiate itself by being the 'only genuine hydrogel DRT,' claiming superior conformability, ease of use, and a biomimetic degradation profile designed for optimal healing kinetics.

More companies in Regenerative Medicine →More companies in United States →